Quarterly ResultAug 4, 2026, 04:10 PM
Personalis Q2 Revenue $22.4M (+30%); Clinical Volume +199%
AI Summary
Personalis reported strong second-quarter 2026 financial results, with total revenue increasing 30% year-over-year to $22.4 million and clinical test volume surging 199% to 10,384 tests. The company also secured Medicare coverage for its NeXT Personal test for IO monitoring and Neoadjuvant Breast Cancer monitoring. However, the net loss widened to $(31.683) million. Due to the pending merger with Tempus AI, Inc., Personalis will no longer provide financial guidance.
Key Highlights
- Total revenue increased 30% year-over-year to $22.4 million in Q2 2026.
- Clinical test volume surged 199% year-over-year to 10,384 tests in Q2 2026.
- Clinical revenue grew 442% year-over-year to $2.6 million.
- Revenue from pharma testing services and other customers increased 51% to $16.8 million.
- Net loss for Q2 2026 was $(31.683) million, compared to $(20.056) million in Q2 2025.
- Ended the quarter with approximately $212.7 million in cash, cash equivalents, and short-term investments.
- Secured Medicare coverage for NeXT Personal for IO monitoring for late-stage solid tumors.
- Secured Medicare coverage for NeXT Personal for Neoadjuvant Breast Cancer monitoring.
Price Impact
More from PSNL